Show All

April 2013

Khan JM, Lyon AR, and Harding SE

The Case for Induced Pluripotent Stem Cell-derived Cardiomyocytes in Pharmacological Screening

Br J Pharmacol 169(2):304-17

Publication Date: April 26, 2013

Product Type: iCell Cardiomyocytes


This review assesses state-of-the art technology as of 2013, noting the advantages, potentials, and limitations of stem cell-derived cardiomyocytes in pharmacological screening.


The data and references within this review provide readers with peer-reviewed demonstrations of stem cell-derived cardiomyocyte utility. Many of the shortcomings and/or gaps in the technology are being (or have been) addressed by CDI.